High-dose Sequential Chemotherapy Versus A Less Intensive Regimen Followed By Peripheral Blood Autologous Hematopoietic Stem Cell Transplantation As Salvage Treatment In Relapsed And Refractory Hodgkin's Disease

Background and Objective. High-dose sequential chemotherapy (HDS) has been given to patients with Hodgkin's disease (HD) before autologous hematopoietic stem cell transplantation (HSCT), but its effectiveness has not been evaluated in comparison with less-aggressive regimens. In this study we compared HDS with a less-aggressive regimen as preparation to autologous HSCT in patients with HD. Design and Methods. Retrospective non-randomized comparison between patients receiving HDS (group 1, n=52) or a less-aggressive regimen (group 2, n=60). HDS consisted of the sequential administration of cyclophosphamide (7 g/m 2) and G-CSF (300 μg/day) with stem cell collection, methotrexate (8 g/m2) plus vincristine (1.4 mg/m2), and etoposide (2 g/m2). Group 2 patients received of 2 cycles of DHAP, followed by cyclophosphamide (1.5 g/m2) plus G-CSF and stem cell collection. Results. Group 1 patients were more likely to have stage IV (40% vs. 13%, p=0.001) and bulky disease (62% vs. 39%, p=0.02) at diagnosis. Disease status after chemotherapy improved in 59% in group 1 and 8% in group 2 (p<0.001), mostly in patients with disease progression (DP): 50% in group 1 (4 CR and 12 PR) and none in group 2 (p<0.001). Treatment-related toxicity occurred in 5/32 patients with DP in group 1, and 0/28 patients in group 2 (p=0.01). Overall survival was 49% in group 1 and 59% in group 2 (p=0.098). Interpretation and Conclusions. HDS seems to be useful in patients with DP, whereas patients with CR do well with less-intensive chemotherapy.278185Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD (1992) N Engl J Med, 327, pp. 1478-1484Connors, J.M., State-of-the-art therapeutics: Hodgkin's lymphoma (2005) J Clin Oncol, 23, pp. 6400-6408Lister, T.A., Crowther, D., Sutcliffe, S.B., Glatstein, E., Canellos, G.P., Young, R.C., Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting (1989) J Clin Oncol, 7, pp. 1630-1636Hasenclever, D., Diehl, V., A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease (1998) N Engl J Med, 339, pp. 1506-1514Loureiro, M., Morais, J.C., Milito, C.B., Portugal, R.D., Pulcheri, W., Spector, N., Expression of Epstein-Barr virus in patients with Hodgkin's disease: Report of 64 cases from Rio de Janeiro, Brazil (2004) J Bras Patol Med Lab, 40, pp. 37-40de Souza, C.A., Vassallo, J., Lorand-Metze, I., Hodgkin's disease in Brazil: A clinicopathologic study (1997) Haematologica, 82, pp. 127-128Spector, N., Nucci, M., Oliveira De Morais, J.C., Maiolino, A., Portugal, R.D., Costa, M.A., Clinical factors predictive of bone marrow involvement in Hodgkin's disease (1997) Leuk Lymphoma, 26, pp. 171-176Canellos, G.P., Niedzwiecki, D., Long-term follow-up of Hodgkin's disease trial (2002) N Engl J Med, 346, pp. 1417-1418Spector, N., Costa, M.A., Morais, J.C., Biasoli, I., Solza, C., De Fatima, G.M., Intensified ABVP chemotherapy for the primary treatment of Hodgkin's disease (2002) Oncol Rep, 9, pp. 439-442Linch, D.C., Winfield, D., Goldstone, A.H., Moir, D., Hancock, B., McMillan, A., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial (1993) Lancet, 341, pp. 1051-1054Schmitz, N., Pfistner, B., Sextro, M., Sieber, M., Carella, A.M., Haenel, M., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial (2002) Lancet, 359, pp. 2065-2071Reece, D.E., Hematopoietic stem cell transplantation in Hodgkin disease (2002) Curr Opin Oncol, 14, pp. 165-170Baldissera, R.C., Aranha, J.F., Oliveira, G.B., Vigorito, A.C., Eid, K.A., Miranda, E.C., High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma (2002) Braz J Med Biol Res, 35, pp. 49-57Ferme, C., Mounier, N., Divine, M., Brice, P., Stamatoullas, A., Reman, O., Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial (2002) J Clin Oncol, 20, pp. 467-475Tarella, C., Cuttica, A., Vitolo, U., Liberati, M., Di, N.M., Cortelazzo, S., High-dose sequential chemotherapy and peripheral blood progenitor cell autografting in patients with refractory and/or recurrent Hodgkin lymphoma: A multicenter study of the intergruppo Italiano Linfomi showing prolonged disease free survival in patients treated at first recurrence (2003) Cancer, 97, pp. 2748-2759Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sienawski, M., Sieber, M., Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG) (2005) Ann Oncol, 16, pp. 116-123Josting, A., Autologous transplantation in relapsed and refractory Hodgkin's disease (2005) Eur J Haematol Suppl, 66, pp. 141-14